Skip to main content
Clinical Trials/NCT05579353
NCT05579353
Recruiting
Not Applicable

The Roles and Molecular Mechanism of Exosomal Circ-LRBA That Regulates miR-451/CRTC2 Signaling Axis in Colorectal Cancer Progression

Jingbo Chen1 site in 1 country200 target enrollmentJanuary 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colorectal Cancer
Sponsor
Jingbo Chen
Enrollment
200
Locations
1
Primary Endpoint
expressional quantity
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Most of the patients with colorectal cancer were diagnosed in poor stage. Although 40% to 50% patients of colorectal cancer can be cured by surgery, but most patients have undergent metastasis or recurrence, and eventually death. In recent years, molecular targeted therapy has shown significant efficacy in specific patients. It was necessary to detect the corresponding molecular targets of tumors before selecting appropriate targeted drugs in clinic. The changing state of related gene molecules in colorectal cancer played a key role in drug selection, there were few effective targets so far. At present, metastasis and recurrence still be the most difficult problems in treatment. Therefore, investigators should deeply study the occurrence and development of colorectal cancer at the gene level and look for new biomarkers to predict the prognosis. Furthermore, the study can clarify the exact molecular mechanism of colorectal cancer. These will be important clinical significance for targeted therapy of colorectal cancer.

Registry
clinicaltrials.gov
Start Date
January 1, 2023
End Date
December 31, 2026
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Jingbo Chen
Responsible Party
Sponsor Investigator
Principal Investigator

Jingbo Chen

Professor

Qianfoshan Hospital

Eligibility Criteria

Inclusion Criteria

  • 1.18-80 years old.
  • 2.18.5 \< BMI \< 27.
  • The surgical methods are radical resection of rectal cancer, resection of right colon cancer, resection of left colon cancer and radical resection of sigmoid colon cancer.

Exclusion Criteria

  • Those who refuse to collect samples.
  • Patients with severe dysfunction of coagulation, hepatorenal dysfunction or severe cardiopulmonary diseases.
  • Patients who has a history of neoadjuvant radiotherapy or chemotherapy.
  • Combining with distant multiple metastases of tumor

Outcomes

Primary Outcomes

expressional quantity

Time Frame: Through study completion, an average of 2 year

Expression of CRTC2 in patient samples

Study Sites (1)

Loading locations...

Similar Trials